Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026

ConferenceRBS2418Neutral

AI Analysis

Summary

Riboscience announced it will present first overall survival and immune activation data from its Phase 1b study of oral ENPP1 inhibitor RBS2418, as monotherapy and in combination, in advanced metastatic cancers including MSS CRC, as a poster at ESMO 2026. No results were disclosed in the excerpt.

Clinical Trial Data

Phase

Phase_1

Outcome Details

Phase 1b data for RBS2418 (monotherapy and combination), including first overall survival and immune activation data, to be presented as a poster at ESMO 2026.

Importance:5/10

Sentiment:

0.20

ESMO 2026ENPP1 inhibitorRBS2418oncologyimmunotherapyMSS CRCPhase 1boral therapyprivate company

Related Companies

$INTI $MDCE $TRAX

Read the original article

Published by PR Newswire Biotech on October 19, 2026 2:07 PM

Read Original